Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioventus Inc. filings document the formal disclosures of a Nasdaq-listed medical device company with Class A common stock registered under the Exchange Act. Recent Form 8-K reports furnish operating results and financial condition updates, including quarterly and annual earnings releases for the company’s active-healing product portfolio.
The company’s regulatory filings also cover proxy governance for annual stockholder meetings, board composition matters, emerging growth company status, credit arrangements entered into by Bioventus LLC and its subsidiaries, and product regulatory events such as FDA 510(k) clearance for TalisMann and StimTrial within the Peripheral Nerve Stimulation portfolio.
Nantahala Capital Management, LLC and two principals report beneficial ownership of 5,280,842 shares of Bioventus Inc. Class A common stock, representing 7.96% of the outstanding class as of June 30, 2025. The filing states the shares are held by funds and separately managed accounts under Nantahala's control and that Nantahala and its managing members, Wilmot B. Harkey and Daniel Mack, share voting and dispositive power over these shares but have no sole voting or dispositive power. The filing is submitted on a Schedule 13G/A indicating the holdings are in the ordinary course of business and not intended to influence control of the issuer. The document includes the issuer address and signatures dated August 14, 2025.
Bioventus Inc. (BVS) entered into a Credit Agreement dated July 31, 2025, establishing a $100 million revolving credit facility and a $300 million first lien term loan A facility, and drew $30 million under the revolver on the Closing Date.
Key terms:
- Total facilities: $400 million ($100M revolver, $300M term loan)
- Maturity: July 31, 2030
- Interest: Term SOFR plus initial margin 2.50% (margin thereafter adjusted quarterly by consolidated total net leverage bands)
- Amortization: Term loan amortizes 5% of original principal annually; balance due at maturity
- Fees: Revolver commitment fee 0.30% (stepdown 0.10% if leverage <2.50x); revolver includes $7.5M letter of credit and $7.5M swingline sub-facilities
- Covenants: secured by substantially all assets; maximum consolidated total net leverage 4.00x (through Q4 2025) then 3.50x thereafter (temporary 0.50x election for certain acquisitions); consolidated interest coverage >=2.50x starting Q3 2025
Bioventus Inc. (BVS) filed a Form 8-K to report that on 30 Jul 2025 the U.S. FDA granted 510(k) clearance for two Peripheral Nerve Stimulation (PNS) devices, TalisMann™ and StimTrial™. The decision permits immediate U.S. marketing without additional clinical trials, expanding Bioventus’ portfolio beyond orthobiologics and bone-healing systems.
No revenue, margin or guidance figures were disclosed, yet management signals a new addressable market in neuromodulation. Clearance could diversify revenue streams and leverage the company’s existing sales infrastructure; however, launch timing, pricing, reimbursement and market-share expectations remain unspecified.
- Item reported: 8.01 – Other Events
- Regulatory milestone: FDA 510(k) clearance
- Products affected: TalisMann & StimTrial PNS devices
- Potential impact: accelerates entry into U.S. PNS market, incremental growth driver